NEW
YORK, May 16, 2022 /PRNewswire/ – Axsome
Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company
developing and delivering novel therapies for the management of
central nervous system (CNS) disorders, is supporting the National
Alliance on Mental Illness (NAMI) during Mental Health Awareness
Month this May to raise awareness of and support for people living
with depression and other mental health conditions. NAMI is the
nation's largest grassroots mental health organization.
Recent figures indicate a high and growing prevalence of mental
illness, with a significant percentage of those afflicted not
receiving treatment:
- 1 in 5 U.S. adults and 1 in 6 youth aged 6-17 experience mental
illness each year.1
- Suicide is the second leading cause of death among people aged
10-34.2
- Between 2020 and 2021, calls to the NAMI HelpLine
(1-800-950-NAMI, or 6264) about depression and anxiety increased by
80%, calls about suicide increased by 185%, and calls about mental
health crises increased by 251%.3
- Among adults with mental illness, only 46% received treatment
in 2020, a number that is even lower among Black (37%),
Hispanic/Latinx (35%), and Asian Americans (21%).1
NAMI's mental health education, advocacy, and support options
for individuals and their families can be accessed at
www.nami.org.
Tips and resources from the National Institute of Mental Health
to help take care of your mental health are available at
https://www.nimh.nih.gov/health/topics/caring-for-your-mental-health.
Resources and tools to help support those affected by depression
are available at www.talkdepressettling.com.
"Axsome stands in solidarity with the millions of
people affected by mental illness and is proud to participate in
NAMI's 2022 'Together for Mental Health' campaign in observance of
Mental Health Awareness Month," said Herriot Tabuteau, MD, Chief Executive Officer of
Axsome. "We look forward to continuing our work to bring national
awareness and dialogue to mental health and address the pressing
need for new and effective treatments to help those living with
depression and other mental health conditions."
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a biopharmaceutical company
developing and delivering novel therapies for central nervous
system (CNS) conditions that have limited treatment options.
Through development of therapeutic options with novel mechanisms of
action, we are transforming the approach to treating CNS
conditions. At Axsome, we are committed to developing products that
meaningfully improve the lives of patients and provide new
therapeutic options for physicians. For more information, please
visit the Company's website at axsome.com. The Company may
occasionally disseminate material, nonpublic information on the
company website.
Forward Looking Statements
Certain matters discussed in this press release are
"forward-looking statements". We may, in some cases, use terms such
as "predicts," "believes," "potential," "continue," "estimates,"
"anticipates," "expects," "plans," "intends," "may," "could,"
"might," "will," "should" or other words that convey uncertainty of
future events or outcomes to identify these forward-looking
statements. In particular, the Company's statements regarding
trends and potential future results are examples of such
forward-looking statements. The forward-looking statements include
risks and uncertainties, including, but not limited to, the
continued commercial success of our newly acquired Sunosi product;
the success, timing and cost of our ongoing clinical trials and
anticipated clinical trials for our current product candidates,
including statements regarding the timing of initiation, pace of
enrollment and completion of the trials (including our ability to
fully fund our disclosed clinical trials, which assumes no material
changes to our currently projected expenses), futility analyses and
receipt of interim results, which are not necessarily indicative of
the final results of our ongoing clinical trials, and the number or
type of studies or nature of results necessary to support the
filing of a new drug application ("NDA") for any of our current
product candidates; our ability to fund additional clinical trials
to continue the advancement of our product candidates; the timing
of and our ability to obtain and maintain U.S. Food and Drug
Administration ("FDA") or other regulatory authority approval of,
or other action with respect to, our product candidates (including,
but not limited to, whether potential filing issues or issues
identified by FDA during the substantive review may impact the
potential approvability of the Company's NDA submission for AXS-05
in MDD or the timing of such approval; whether issues identified by
FDA in the complete response letter may impact the potential
approvability of the Company's NDA for AXS-07 for the acute
treatment of migraine in adults with or without aura, pursuant to
our special protocol assessment for the MOMENTUM clinical trial;
the potential for the ASCEND clinical trial, combined with the
GEMINI clinical trial results, to provide a basis for approval of
AXS-05 for the treatment of major depressive disorder and
accelerate its development timeline and commercial path to
patients; the Company's ability to successfully defend its
intellectual property or obtain the necessary licenses at a cost
acceptable to the Company, if at all; the successful implementation
of the Company's research and development programs and
collaborations; the success of the Company's license agreements;
the acceptance by the market of the Company's product candidates,
if approved; the Company's anticipated capital requirements,
including the amount of capital required for the continued
commercialization of Sunosi and for the Company's commercial launch
of its product candidates, and the potential impact on the
Company's anticipated cash runway; unforeseen circumstances or
other disruptions to normal business operations arising from or
related to COVID-19; and other factors, including general economic
conditions and regulatory developments, not within the Company's
control. The factors discussed herein could cause actual results
and developments to be materially different from those expressed in
or implied by such statements. The forward-looking statements are
made only as of the date of this press release and the Company
undertakes no obligation to publicly update such forward-looking
statements to reflect subsequent events or circumstance.
Axsome Contact:
Mark
Jacobson
Chief Operating Officer
Axsome Therapeutics, Inc.
22 Cortlandt Street, 16th Floor
New York, NY 10007
Tel: 212-332-3243
Email: mjacobson@axsome.com
www.axsome.com
References
- Substance Abuse and Mental Health Services Administration.
(2021). Results from the 2020 National Survey on Drug Use and
Health. Retrieved from https://www.samhsa.gov/data/
- Centers for Disease Control and Prevention (CDC). (2019).
WISQARS Leading Causes of Death Reports. Retrieved from:
https://www.cdc.gov/injury/wisqars/index.html
- National Alliance on Mental Illness. (2
May 2022). Press Release.
:
View original content to download
multimedia:https://www.prnewswire.com/news-releases/axsome-therapeutics-supports-the-national-alliance-on-mental-illness-nami-to-recognize-mental-health-awareness-month-301547520.html
SOURCE Axsome Therapeutics Inc